Critically evaluate industry–academia linkages in India's pharma-MedTech R&D ecosystem, with reference to the NIPER Centres of Excellence.

India is called the "pharmacy of the world" because of its low-cost generics, but it has a weak record in drug discovery. To change this, the ₹5,000 crore PRIP scheme was launched alongside a National R&D Policy. One of its stated aims is to promote industry–academia linkage [1]. The linkage is well designed but has delivered little so far.

Strengths: design of the linkage

• Dedicated research base: Component A funds 7 Centres of Excellence (CoEs) at NIPERs with about ₹700 crore [1].
• Specialised to industry's needs: Mohali covers anti-bacterial and anti-viral drug discovery, Ahmedabad medical devices, Hyderabad bulk drugs and Guwahati phytopharmaceuticals [3].
• Money for joint projects: Component B sets aside ₹4,250 crore for industry and start-ups, including projects with academic partners [4].
• Links beyond funding: a planned digital innovation exchange will connect innovators with investors, mentors and ICMR's Patent Mitra and MedTech Mitra [5].

Weaknesses: delivery on the ground

• Slow build-out: the PM laid foundation stones for four CoEs only in October 2024 [3]. Just ₹183.46 crore had been released to the seven CoEs by January 2026 [2], about a quarter of the outlay.
• Academia hard to see in the results: the first round approved 41 projects worth ₹1,600 crore. Firms led them, such as Biocon, Sun Pharma and Zydus, along with 19 start-ups and MSMEs [6]. The CoEs do not appear as partners.
• Weak research culture in industry: the PRDC benchmark says an R&D-intensive firm should spend 5% of its turnover on research [7]. The generics model rewards low cost, not discovery. PRIP itself treats this as the problem to fix [4].
• Too few institutions: Component A covers only seven NIPERs [1]. The wider university and medical-college research base is not part of it.

India now has the basic structure for industry–academia linkage, but the linkage is still at an early stage in practice. The way forward:

• Release CoE funds faster.
• Reserve part of Component B for CoE–industry consortia.
• Publish clear rules on sharing IP (intellectual property).
• Track joint patents and licences as outcomes.

These steps would turn PRIP's shift from cost-based to innovation-based growth into real results. They also advance Atmanirbhar Bharat and SDG 3 and SDG 9 (health; industry and innovation).